Research progress on the economic evaluation of chickenpox and varicella vaccine

Abstract

Abstract: Chickenpox is highly contagious and prone to outbreaks,especially in children,and widely prevalent worldwide. As an effective means to prevent the onset of chickenpox,the economic evaluation of varicella vaccine is of great significance to guide vaccination strategies. This article aims to provide a comprehensive overview of the epidemiological characteristics of varicella and to provide a general overview of the economic evaluation of varicella vaccines. At the same time,summarize the results of the current economic evaluation of varicella vaccine and points out the shortcomings,in order to provide a reference for the formulation of varicella vaccination strategy and related economic research in China.

Key words: Chickenpox, Popular characteristics, Economic evaluation

CLC Number:

R186

Gulijiayina Aiken, ZHOU Yiran, ZHANG Yuhang, CHEN Wei, YU Jing, LU Yaoqin. Research progress on the economic evaluation of chickenpox and varicella vaccine[J]. OCCUPATION AND HEALTH, 2025, 41(17): 2434-2438.

References

[1] FENG H,ZHANG H,MA C,et al.National and provincial burden of varicella disease and cost-effectiveness of childhood varicella vaccination in China from 2019 to 2049:A modelling analysis[J].Lancet Reg Health West Pac,2023,32:100639.
[2] LEE Y H,CHOE Y J,HWANG S S,et al.Spatiotemporal distribution of varicella in the republic of Korea[J].J Med Virol,2022,94(2):703-712.
[3] FREER G,PISTELLO M.Varicella-zoster virus infection:Natural history,clinical manifestations,immunity and current and future vaccination strategies[J].New Microbiol,2018,41(2):95-105.
[4] SUMI A.Role of temperature in reported chickenpox cases in northern European countries:Denmark and Finland[J].BMC Res Notes,2018, 11(1):377.
[5] ÁVILA A M L,BELTRAN S,CASTILLO J B D,et al.Varicella epidemiology in latin america and the caribbean[J].Expert Rev Vaccines,2018, 17(2):175-183.
[6] WANG Z,HE J,JIN B,et al.Using baidu index data to improve chickenpox surveillance in Yunnan,China:Infodemiology study[J].J Med Internet Res,2023,25:e44186.
[7] CHENG T,BAI Y,SUN X,et al.Epidemiological analysis of varicella in dalian from 2009 to 2019 and application of three kinds of model in prediction prevalence of varicella[J].BMC Public Health,2022, 22(1):678.
[8] 陆晓娟,蒋雪峰,郭林杰,等.平湖市2010—2020年水痘发病流行特征及疫苗免疫效果分析[J].现代实用医学,2024,36(1):45-48.
[9] 张庭婷. 2015—2020年六安市气象因素对水痘发病的短期影响:基于分布滞后非线性模型的研究[D].合肥:安徽医科大学,2023.
[10] HUANG J,WU Y,WANG M,et al.The global disease burden of varicella-zoster virus infection from 1990 to 2019[J].J Med Virol,2022, 94(6):2736-2746.
[11] MIRANDA K U,DEANTONIO R,NORERO X,et al.The impact of varicella vaccination:A 2005—2019 interrupted time series analysis[J].Hum Vaccin Immunother,2023,19(3):2278927.
[12] BARDSLEY M,LOVERIDGE P,BEDNARSKA N G,et al.The epidemiology of chickenpox in England,2016—2022:An observational study using general practitioner consultations[J].Viruses,2023,15(11):2163.
[13] LIU B,LI X,YUAN L,et al.Analysis on the epidemiological characteristics of varicella and breakthrough case from 2014 to 2022 in Qingyang city[J].Hum Vaccin Immunother,2023,19(2):2224075.
[14] 熊书晗. 2009—2018年吉林省水痘的流行特征和空间聚集性研究[D].长春:吉林大学,2020.
[15] BAKKER K M,MARTINEZ B M E,HELM B,et al.Digital epidemiology reveals global childhood disease seasonality and the effects of immunization[J].Proc Natl Acad Sci U S A,2016,113(24):6689-6694.
[16] 李轩,卫宪钰,张文义,等.水痘流行病学特征及影响因素研究进展[J].疾病监测,2023,38(7):878-883.
[17] 董蒲梅,王淼,刘燕敏.2016—2019年中国水痘流行病学特征[J].中国疫苗和免疫,2020,26(4):403-406.
[18] 随海田,李锦成,王淼,等.2005—2015年中国水痘流行病学特征[J].中国疫苗和免疫,2019,25(2):155-159.
[19] 王淼,曾祥,张一平,等.中国2007—2021年水痘突发公共卫生事件流行病学特征[J].中国疫苗和免疫,2023,29(3):274-279.
[20] WANG M,LI X,YOU M,et al.Epidemiological characteristics of varicella outbreaks-China,2006—2022[J].China CDC Wkly,2023,5(52):1161-1166.
[21] RUDMIK L,DRUMMOND M.Health economic evaluation:Important principles and methodology[J].Laryngoscope,2013,123(6):1341-1347.
[22] HIGGINS A M,HARRIS A H.Health economic methods:Cost-minimization,cost-effectiveness,cost-utility,and cost-benefit evaluations[J].Crit Care Clin,2012,28(1):11-24.
[23] 柳鸿鹏,吴欣娟.国外卫生经济学评价的研究进展[J].中华现代护理杂志,2020,26(24):3394-3397.
[24] BRENT R J.Cost-benefit analysis versus cost-effectiveness analysis from a societal perspective in healthcare[J].Int J Environ Res Public Health,2023,20(5):4637.
[25] ROBINSON R.Cost-utility analysis[J].BMJ,1993,307(6908):859-862.
[26] 刘国恩. 中国药物经济学评价指南(2020中英双语版)[M].北京:中国市场出版社,2020:4-5.
[27] 陶立波. 社会视角和医院视角下卫生经济学评估的内在矛盾及其协调机制[J].中国卫生政策研究,2018,11(4):61-63.
[28] 刘彩念,余正,唐守胜.疫苗药物经济学评价中有关成本和效果的测算方法探讨[J].中国药物经济学,2011(5):6-11.
[29] 陈俊泽,曾雁冰,方亚.疫苗经济学评价中的数学模型研究进展[J].中国卫生统计,2016,33(6):1092-1096.
[30] 王李婷,彭六保,彭烨,等.2020年版和2011年版中国药物经济学评价指南比较分析[J].中国药物经济学,2021,16(3):5-8,15.
[31] BANZ K,ISELI A,AEBI C,et al.Economic evaluation of varicella vaccination in Swiss children and adolescents[J].Hum Vaccin,2009,5(12):847-857.
[32] WOLFF E,WIDGREN K,SCALIA T G,et al.Cost-effectiveness of varicella and herpes zoster vaccination in Sweden:An economic evaluation using a dynamic transmission model[J].PLoS One,2021,16(5):e0251644.
[33] CHACON C E,MEROC E,COSSTA C S A,et al.Economic evaluation of universal varicella vaccination in Mexico[J].Pediatr Infect Dis J,2022, 41(5):439-444.
[34] MARIJAM A,SAFONOVA E,SCHERBAKOV M,et al.Cost effectiveness and budget impact of universal varicella vaccination in Russia[J].Hum Vaccin Immunother,2022,18(5):2045152.
[35] PAWASKAR M,BURGESS C,PILLSBURY M,et al.Clinical and economic impact of universal varicella vaccination in Norway:A modeling study[J].PLoS One,2021,16(7):e0254080.
[36] RAFFERTY E R S,MCDONALD W,OSGOOD N D,et al.What we know now:An economic evaluation of chickenpox vaccination and dose timing using an agent-based model[J].Value Health,2021,24(1):50-60.
[37] AHERN S,BROWNE J,MURPHY A,et al.An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland[J].Vaccine,2024, 42(14):3321-3332.
[38] HALLORAN M E.Epidemiologic effects of varicella vaccination[J].Infect Dis Clin North Am,1996,10(3):631-655.
[39] BOELLE P Y,HANSLIK T.Varicella in non-immune persons:Incidence,hospitalization and mortality rates[J].Epidemiol Infect,2002, 129(3):599-606.
[40] BRISSON M,EDMUNDS W J,GAY N J,et al.Modelling the impact of immunization on the epidemiology of varicella zoster virus[J].Epidemiol Infect,2000,125(3):651-669.
[41] HEININGER U,PILLSBURY M,SAMANT S,et al.Health impact and cost-effectiveness assessment for the introduction of universal varicella vaccination in Switzerland[J].Pediatr Infect Dis J,2021,40(6):e217-e221.
[42] AZZARI C,BALDO V,GIUFFRIDA S,et al.The cost-effectiveness of universal varicella vaccination in Italy:A model-based assessment of vaccination strategies[J].Clinicoecon Outcomes Res,2020,12:273-283.
[43] 左丽娟. 藏族寄宿学生接种水痘减毒活疫苗的卫生经济学分析[J].职业与健康,2013,29(5):634-635.
[44] 梁亦好. 在澳门推行儿童水痘疫苗常规接种的经济学评价[D].北京:中国疾病预防控制中心,2007.
[45] 涂正波,徐群英,万刚凤,等.南昌市红谷滩新区水痘经济负担及疫苗免疫的成本效益分析[J].中国公共卫生管理,2019,35(2):164-167.
[46] 吕鸿鑫,古子豪,罗经伟.应急接种对校园水痘疫情的经济负担影响[J].实用预防医学,2022,29(1):14-17.
[47] WANG Q,XIU S,YANG L,et al.Economic evaluation of varicella vaccination strategies in Jiangsu province,China:A decision-tree Markov model[J].Hum Vaccin Immunother,2021,17(11):4194-4202.
[48] 张夏晴,邵灵,秦伟,等.应用决策树-Markov模型分析1剂次和2剂次水痘减毒活疫苗免疫策略的成本效用[J].中国疫苗和免疫,2024, 30(2):205-211.
[49] 殷大鹏. 中国水痘疫苗免疫策略评价和成本效益分析[D].北京:中国疾病预防控制中心,2015.
[50] 张晓曙,王晓玲,李慧.应用EVITA模型对甘肃省水痘疫苗接种的经济学评价[J].中国卫生经济,2012,31(3):76-78.
[51] 邓璇,何寒青,周洋,等.水痘疫苗不同免疫策略的卫生经济学评价[J].浙江大学学报(医学版),2018,47(4):374-380.